The immune checkpoint inhibitor (ICI), nivolumab, has revolutionised the treatment of
recurrent and metastatic oral cancer. However, the response rate to ICIs remains low, and …

OBJECTIVE: Worldwide, head and neck carcinomas account for 5% of all malignancies.
Two-thirds of patients relapse after initial multimodal therapy. Until early 2000, the median …

Abstract Objectives/Hypothesis: To determine if the various imaging modalities for distant
metastasis (DM) diagnosis alters life expectancy in head and neck squamous cell carcinoma …

Throughout the last 2 decades, great strides have been made in managing patients with
locally advanced head and neck squamous cell carcinoma. In many clinical settings, they …

We evaluated objective and subjective swallowing function outcomes in patients with
dysphagia treated for head and neck cancer (HNC) and identified risk factors for poor …

This paper documents the process by which we, through gene and miRNA expression
profiling of the same samples of head and neck squamous cell carcinomas (HNSCC) and an …

Background In patients with recurrent or metastatic head and neck squamous cell carcinoma
(R/M HNSCC) the estimated prognosis is usually poor. Patient-specific factors that affect …

Aim The aims of the study are to evaluate the clinical outcomes of first-line treatment with
platinum-based chemotherapy and cetuximab in patients with relapsing/metastatic head and …

Single agent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have
demonstrated reproducible response rates of 5–15% in treatment of squamous cell …

For palliation of patients with recurrent and/or metastatic head and neck squamous cell
cancer (R/M HNSCC), the major classes of commonly used cytotoxic chemotherapeutic …